can tirzepatide cause palpitations Should a patient with tachycardia stop taking (glucagon-like peptide-1 (GLP-1) receptor agonist)? Mounjaro Heart Benefits – What
Description
Debra L
Exp Mol Med 56 , 24492464 (2024)
Among those who do, the majority describe it as mild to moderate and manageable with basic interventions
Understanding this timeline helps set realistic expectations and identify whether your current dose is optimally matched to your biology
Sitagliptin is not extensively bound to plasma proteins
These decisions come from a full health history review and should be determined by a qualified healthcare professional
